News
Prehabilitation and early screening, including BIS, can ease recovery, reduce side effects and help manage lymphedema after ...
In a phase 2 study, 52% of patients treated with Bria-IMT plus a checkpoint inhibitor for metastatic breast cancer were alive at one year.
A cancer thriver reflects on the emotional toll, survivorship, advocacy and support networks they wish they’d known at ...
It took years to understand why my mastectomy site looked different. Knowing I healed correctly for my procedure helped me ...
New clinical trials are advancing in hard-to-treat cancers, offering targeted and less toxic options for patients with ...
I’ve survived rare blood cancer for 15 years, but the lasting side effects have taken a toll — even so, I still find purpose, ...
The FDA granted orphan drug designation to a CAR T-cell therapy for recurrent glioblastoma and high-grade astrocytomas.
The FDA approved SIR-Spheres Y-90 resin microspheres for unresectable liver cancer, the only radioembolization approved in ...
Dr. Nicholas James discusses why it is important to identify which patients with high-risk prostate cancer will truly benefit ...
Cancer is nonpartisan. It touches everyone — cutting across religion, race, ethnicity, sexual orientation and socioeconomic ...
Nine years after my bladder cancer diagnosis, I reflect on its recurrence, caregiving, grief, and my new life with leukemia ...
Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice and return to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results